Eliem Therapeutics Price to Free Cash Flow Ratio 2021-2024 | CLYM
Historical price to free cash flow ratio values for Eliem Therapeutics (CLYM) since 2021.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Eliem Therapeutics Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-10-03 |
5.10 |
|
0.00 |
| 2024-03-31 |
2.74 |
$-0.26 |
0.00 |
| 2023-12-31 |
2.70 |
$-0.76 |
0.00 |
| 2023-09-30 |
2.63 |
$-2.06 |
0.00 |
| 2023-06-30 |
2.80 |
$-1.18 |
0.00 |
| 2023-03-31 |
2.90 |
$-1.05 |
0.00 |
| 2022-12-31 |
3.67 |
$-1.01 |
0.00 |
| 2024-06-30 |
7.11 |
$-0.08 |
0.00 |
| 2022-09-30 |
3.23 |
$-2.23 |
0.00 |
| 2022-06-30 |
3.02 |
$-3.88 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
